Organizers of gene-editing meeting blast Chinese study but call for ‘pathway’ to human trials
By Dennis Normile,
Science [cites CGS]
| 11. 29. 2018
HONG KONG, CHINA—An international conference on human gene editing dominated by news of the birth of the world's first genetically engineered babies concluded today with a statement from the organizers that harshly condemned the controversial study. But it did not call for a global moratorium on similar studies, as some scientists had hoped; instead it called for a "translational pathway" that might eventually bring the ethically fraught technology to patients in a responsible way.
The hotly debated study, which apparently resulted in twin baby girls whose genomes were altered in a way that could affect their offspring, came to light on the eve of the second International Summit on Human Genome Editing here. The first summit, held in Washington, D.C., in December 2015, concluded with a statement that specifically said that unless and until safety, efficacy, and ethical and regulatory issues are resolved, "it would be irresponsible to proceed with any clinical use of germline editing," a reference to genetic modifications that can be passed on to the next generation.
But that is exactly what Chinese researcher He Jiankui...
Related Articles
By Aisha Down, The Guardian | 11.10.2025
It has been an excellent year for neurotech, if you ignore the people funding it. In August, a tiny brain implant successfully decoded the inner speech of paralysis patients. In October, an eye implant restored sight to patients who had...
By Jessica Hamzelou, MIT Technology Review | 11.07.2025
This week, we heard that Tom Brady had his dog cloned. The former quarterback revealed that his Junie is actually a clone of Lua, a pit bull mix that died in 2023.
Brady’s announcement follows those of celebrities like Paris...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...